Navigation Links
Relmada Therapeutics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
Date:9/3/2014

NEW YORK, Sept. 3, 2014 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company"), today announced it will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2014, at The Palace Hotel in New York City.

Sergio Traversa, CEO of Relmada Therapeutics, will provide an update on the Company during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

Event: 16th Annual Rodman & Renshaw Global Investment Conference
Date: September 10, 2014
Time: 2:05 p.m. (Eastern Time)
Location: Kennedy II (4th Floor); the Palace Hotel in New York City

If you are an institutional investor, and would like to attend the Relmada's presentation, please click on the following link (www.rodm.com) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Sergio Traversa.

The Relmada presentation will also be available via a live webcast. To access the webcast, please visit www.rodm.com or http://wsw.com/webcast/rrshq24/rlmd. The webcast replay will remain available for 90 days following the live presentation.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical stage, public specialty pharmaceutical company, focused on developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at different stages of development and a deep early stage pipeline. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team with inputs from a world-class scientific advisory board. The Company's approach is expected to reduce overall clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.

About Rodman & Renshaw Conferences, LLC –

The Rodman & Renshaw Annual Global Investment Conference is an informational service and networking opportunity for companies and investors. Rodman does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Rodman is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Rodman soliciting any offers to buy or sell any security of any company.

Forward-Looking Statements

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements.  The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected.  Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.  Visit our website at, www.relmada.com


'/>"/>
SOURCE Relmada Therapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Relmada Therapeutics, Inc. Completes Name Change and Announces New Ticker
2. Relmada Therapeutics Inc. Appoints Douglas J. Beck As Chief Financial Officer
3. Relmada Therapeutics Announces LevoCap ER Development Progress
4. Nabriva Therapeutics Appoints Dr Colin Broom as Chief Executive Officer
5. Mast Therapeutics To Present At The Rodman And Renshaw 16th Annual Global Investment Conference On September 9th
6. Mast Therapeutics Announces Management Change
7. Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014
8. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT
9. Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM
10. ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations
11. Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ALEXANDRIA, Va. , Feb. 12, 2016  This ... & Specialty Pharmacy (JMCP) takes an in-depth look ... the recent spike in prescription drug spending, which has ... JMCP Editor-in-Chief Laura E. Happe ... Laura E. Happe , PharmD, MPH. --> ...
(Date:2/12/2016)... , February 12, 2016 /PRNewswire/ ... nicht anders vermerkt)   http://www.sedar.com ... http://www.telestatherapeutics.com abrufbar.    --> ... des Unternehmens http://www.telestatherapeutics.com abrufbar.    ... (TSX:TST; PNK:BNHLF) veröffentlichte heute seinen Konzernabschluss des ...
(Date:2/12/2016)... VIEJO, Calif. , Feb. 12, 2016  Sequent ... enrollment in a study to evaluate the safety and ... for the treatment of ruptured intracranial aneurysms.  Prof ... University Hospital, in Paris, France ... first patient. France and ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... Good news ... first in the area to offer AngioPlex™ Optical Coherence Tomography (OCT) Angiography, imaging ... as macular degeneration, diabetic retinopathy, and other vascular conditions. , In just a ...
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... With FCPX ... overlays to footage all within Final Cut Pro X. Each user can select from ... 3D rotation, angle of view, blur, focus offset, hue, saturation, value, contrast, glow, and ...
(Date:2/13/2016)... ... ... In the early or “honeymoon” stage of a relationship, couples strive to ... way to be romantic, and may exaggerate a strength or two in an effort ... , A recent study from Queendom.com , however, suggests that new couples ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed to ... students from U.S. universities who will draw from Siemens’ deep knowledge of ...
(Date:2/12/2016)... ... February 12, 2016 , ... As a former television executive, owner Tal Rabinowitz ... no time to decompress, Rabinowitz found herself drawn to a casual meditation class while ... on her life, implementing a 20-minute-per-day meditation practice with her team. After her tenure ...
Breaking Medicine News(10 mins):